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Abstract
Idiopathic pulmonary fibrosis is a lethal lung fibrotic disease, associated with aging 
with a mean survival of 2- 5 years and no curative treatment. The GSE4 peptide is 
able to rescue cells from senescence, DNA and oxidative damage, inflammation, and 
induces telomerase activity. Here, we investigated the protective effect of GSE4 ex-
pression in vitro in rat alveolar epithelial cells (AECs), and in vivo in a bleomycin 
model of lung fibrosis. Bleomycin- injured rat AECs, expressing GSE4 or treated with 
GSE4- PLGA/PEI nanoparticles showed an increase of telomerase activity, decreased 
DNA damage, and decreased expression of IL6 and cleaved- caspase 3. In addition, 
these cells showed an inhibition in expression of fibrotic markers induced by TGF- β 
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1 |  INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is an age- associated 
chronic, progressive, and lethal lung disorder of unknown 
etiology with few therapeutic options that modify its natu-
ral history.1 The disease occurs in middle aged and elderly 
adults, although the familial forms (FPF) may present in 
younger individuals. Lung fibrosis is an aberrant wound 
healing response after alveolar injury characterized by the 
presence of lung scarring with immune and mesenchymal 
abnormalities, in which the restitution of epithelial integrity 
and tissue function are compromised. The mechanisms re-
sponsible for the defective repair and regeneration are poorly 
understood. However, recent studies suggest a possible role 
of accelerated aging and telomere attrition in the onset of the 
disease mainly associated to the familiar forms.2 Therapies 
based on anti- inflammatory agents have little impact on dis-
ease progression,3 although recent findings on the role of IL- 
11 are promising.4 Anti- fibrotic therapy based on the small 
molecules nintedanib5 and pirfenidone6 have been approved 
for the treatment of IPF, but both drugs show important tox-
icities. Furthermore, although new drugs have been used in 
clinical trials,7 no relevant results have been reported, there-
fore, new approaches are needed to advance in the treatment 
of IPF.
Telomere shortening contributes to physiological aging 
and to age- related diseases.8,9 Animal models have shown that 
with increased age or telomere attrition, the lungs become 
highly susceptible to injury and can develop progressive fi-
brosis without the need for repetitive injury.10,11 Mutations 
in telomerase and shelterin genes cause accelerated telomere 
shortening and several telomere syndromes. Mutations in 
TERT, TERC, TINF2, RTEL, PARN, NAF1, ACD, NOP10, 
NHP2, and DKC1 have been identified in pulmonary fibro-
sis.12- 16 Interestingly, telomere shortening has been found in 
25% of IPF and 50% of FPF patients.17 The mechanism by 
which telomere shortening induces lung fibrosis is not well 
understood but some reports suggest an increase of cell se-
nescence (in both fibroblasts and alveolar cells), induction 
of profibrotic pathways such as transforming growth factor 
(TGF- β/Smads signaling)18 and alveolar stem cell failure.19 
Intratracheal administration of bleomycin in rats or mice 
has been widely used to study lung injury and fibrosis and 
to evaluate anti- fibrotic therapies. Mice with telomere short-
ening die when challenged with bleomycin, indicating an 
essential role of telomerase in alveolar cell repair19 and in 
senescence prevention.20
The transforming growth factor beta (TGF- β) pathway, 
among others, is considered as a central driver of patho-
genesis of IPF.18 Activated fibroblasts or myofibroblasts 
have been described as the source of extracellular matrix 
(ECM) deposition during fibrogenesis. However, evidence 
from animal models and in vitro studies has suggested an 
implication of alveolar type II cells (AECII) by induction 
of epithelial mesenchymal transition.21- 23 In IPF lungs, ac-
tivated AECII express several cytokines such as platelet- 
derived growth factor (PDGF), TGF- β1, tumor necrosis 
factor (TNF), endothelin- 1, connective tissue growth fac-
tor (CTGF), osteopontin, and CXC chemokine ligand 
12 (CXCL12), and promote profibrotic responses.7,24,25 
Human AECII are able to undergo, in vitro, a phenotypic 
change upon TGF- β- stimulation and acquire the capability 
to produce collagen as well as display phenotypic changes 
on gene expression that resemble Type 2 EMT. Therefore, 
in addition to activated fibroblasts, these cells might con-
tribute to the pool of collagen- secreting cells in the alveolar 
compartment during wound healing processes or fibrotic 
reactions.26
We have previously described that a 55 amino acids- long 
fragment of the dyskerin TruB domain, named GSE24.2, 
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such as collagen- I and III among others. Furthermore, treatment with GSE4- PLGA/
PEI nanoparticles in a rat model of bleomycin- induced fibrosis, increased telomerase 
activity and decreased DNA damage in proSP- C cells. Both in preventive and thera-
peutic protocols GSE4- PLGA/PEI nanoparticles prevented and attenuated lung dam-
age monitored by SPECT- CT and inhibited collagen deposition. Lungs of rats treated 
with bleomycin and GSE4- PLGA/PEI nanoparticles showed reduced expression of 
α- SMA and pro- inflammatory cytokines, increased number of pro- SPC- multicellular 
structures and increased DNA synthesis in proSP- C cells, indicating therapeutic ef-
ficacy of GSE4- nanoparticles in experimental lung fibrosis and a possible curative 
treatment for lung fibrotic patients.
K E Y W O R D S
alveolar cells, GSE4, pulmonary fibrosis, telomerase
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and a shorter derived peptide, GSE4, have protective effects 
on dyskeratosis congenita (DC) and ataxia telangiectasia 
(AT) patient cells.27- 30 GSE4 peptide increased telomerase 
activity and reduced DNA damage, oxidative stress, cell 
senescence, and increased DNA synthesis in DC and AT 
patient cells.29 GSE4 expression also activated TERT pro-
moter and increased TERT and TERC gene expression.29 
Taking into account the effect that GSE4 has on DNA dam-
age in different disease model cell systems,27- 30 and the 
role of DNA damage and oxidative damage in lung injury 
during fibrosis pathology, we explored the possible thera-
peutic effect of GSE4 in IPF. Using PLGA/PEI nanopar-
ticles as a drug delivery system, we aimed to explore the 
effects of GSE4 expression or GSE4- PLGA nanoparticles 
treatment in alveolar epithelial cells and in a rat model of 
lung fibrosis.30- 32 Our results demonstrated that expression 
of GSE4 increased telomerase activity, decreased DNA 
damage, inflammatory cytokine levels and apoptosis in 
rat type II alveolar cells. Moreover, in rats treated with 
bleomycin, GSE4- PLGA/PEI nanoparticles prevented and 
reduced pulmonary fibrosis as detected by imaging and his-
tological techniques. Our results suggest that GSE4 should 
be considered as a new potential treatment for patients with 
pulmonary fibrosis.
2 |  MATERIALS AND METHODS
2.1 | Cell lines
RLE- 6TN (ATCC CRL- 2300) cell line was purchased from 
ATCC (Manassas VA, USA). Cells were cultured in HAM´s 
F12 (Gibco, Life Technologies, Thermo Fisher Scientific, 
Waltham, MA, USA) and supplemented with fetal bovine 
serum (FBS) (Gibco), penicillin (100 U/mL)/streptomycin 
(100 μg/mL) solution (Gibco), 2 mM L- glutamine (Gibco), 
0.01  mg/mL bovine pituitary extract (Gibco), 0.005  mg/
mL insulin (Gibco), 2.5  ng/mL insulin- like growth factor 
(Gibco), 0.00125  mg/mL transferrin (Gibco), and 2.5  ng/
mL EGF (Gibco) and maintained at 37°C in a humidified 5% 
CO2 atmosphere.
2.2 | Western blot analysis
2.2.1 | Antibodies
The source of antibodies was as follows: phospho- Histone 
H2A.X Ser139 (2577; Cell Signaling Technology, Danvers, 
MA, USA), phospho- p38 and p38 (Th180/tyr182 (9211; 
Cell Signaling), caspase 3 (9662; Cell Signaling) α- tubulin 
(T9026; Sigma- Aldrich Inc Missouri, USA), and anti- 
Phospho- p53 (ser15, 9284; Cell Signaling).
2.2.2 | Western blot
Whole cell extracts from RLE- 6TN were prepared using 
lysis buffer (25 mM HEPES pH 7.5, 0.3 mM NaCl, 1.5 mM 
MgCl2, 0.2  mM EDTA, 20  mM β- glycerophosphate, and 
0.1% Triton X- 100) and a protease inhibitor cocktail 
(0.5  mM ABSF, 2  μg/mL Leupeptin, 2  μg/mL aprotinin, 
0.5 mM DTT, and 0.1 mM Na3VO4). Lysates were centri-
fuged and protein concentration was measured by using the 
Bio- Rad protein assay (500- 0006; Bio- Rad Hercules, CA, 
USA). A 20 μg of protein extracts were resolved on SDS- 
polyacrylamide and electroblotted to Immobilon P mem-
branes (Millipore, Thermo Fisher Scientific, Waltham, 
MA, USA). Western blot analysis was conducted by using 
ECL reagent (Santa Cruz Biotechnology, Dallas, TX, 
USA).
2.3 | Immunofluorescence and Telomere- 
Induced Foci evaluation
Protein localization was carried out by fluorescence micros-
copy. For this purpose, cells were grown on coverslips, trans-
fected and fixed in 3.7% of formaldehyde solution (47 608; 
Fluka, Sigma- Aldrich Inc Missouri, USA) at room tempera-
ture for 15 minutes. After washing with 1x PBS, cells were 
permeabilized with 0.2% of Triton X- 100 in PBS and blocked 
with 10% of horse serum before overnight incubation with 
anti- γ- H2A.X antibody, (05- 636; Merck Millipore, Thermo 
Fisher Scientific, Waltham, MA, USA). Finally, cells were 
washed and incubated with secondary antibodies coupled 
to fluorescent dyes (Alexa Fluor 488 or/and Alexa Fluor 
647). At least 200 cells were quantified in each experimental 
condition.
For Telomere- induced foci (TIF) evaluation cells were 
co- immuno stained with anti- TRF1 and anti- γ- H2A.X an-
tibodies. Imaging was carried out at room temperature in 
Vectashield, mounting medium for fluorescence (Vector 
Laboratories, Burlingame, USA). Images were acquired 
with a Confocal Spectral Leica TCS SP5. Microscope using 
an HCX PL APO Lambda blue 6361.40 OIL UV, zoom 2.3 
lens using LAS- AF 1.8.1 Leica software and processed using 
LAS- AF 1.8.1 Leica software and Adobe Photoshop CS. Co- 
localization of TRF1 and γ- H2A.X was quantified in at least 
200 cells in each condition.
2.4 | Rat model of bleomycin- induced 
lung fibrosis
Animal studies were made in accordance with European 
Community Directive and Spanish guidelines for 
the use of experimental animals and approved by the 
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institutional committee of animal care and research. To check 
if  GSE4- nanoparticles were able to reach the lungs and rescue 
telomerase activity in rats, we used Wistar rats (Wistar Han, 
9 weeks old and weighing 250- 350 g) that were inoculated 
intraperitoneal once with GSE4- nanoparticles (equivalent of 
15 µg peptide/200 gr rat) and 24 hours later intratracheal in-
stilled with a single dose of bleomycin (Bleo) (3.75 U/kg) to 
induce lung injury.33- 35 Three days later lungs were isolated, 
one lung was used for protein extraction for TRAP assays 
and the other for immunohistochemistry analysis. Twenty- 
four rats were used for each experiment and were divided 
into four groups: control- PBS (n = 4), control- GSE4 (n = 4), 
Bleo- PBS (n = 8), and Bleo- GSE4 (n = 8). The study was 
repeated three times.
For pharmacological studies, we used the same rat model 
that facilitated imaging studies and tissue availability and two 
different pharmacological models. In the preventive model, 
Wistar rats were intratracheal instilled with a single dose of 
bleomycin (Bleo) (3.75 U/kg) to induce lung injury, GSE4- 
nanoparticles (equivalent of 15  µg peptide/200 gr rat) or 
vehicle (filtered Phosphate- Buffered Saline- PBS) were ad-
ministered intraperitoneal from day −1 and every 96 hours 
for 14 days. The therapeutic protocol was exactly the same 
but starting GSE4- nanoparticles administration on day 5 
after Bleo instillation, and then, repeated every 96 hours for 
9 days. Twenty- six rats were used for each experiment and 
divided in four groups: control- PBS (n = 4), control- GSE4 
(n = 4), Bleo- PBS (n = 8), Bleo- GSE4 (n = 8), and two rats 
were only observed as sham. Each experimental study was 
repeated three times.
Animals were weighed periodically throughout the proce-
dure and their evolution was controlled using a multimodal 
imaging system micro- Single Photon Emission Tomography 
(SPECT)/Computed Tomography (CT)). At the end of the treat-
ment period, rats were euthanized and lungs were extracted. 
Rats were used according to protocols approved by Comunidad 
de Madrid and CSIC animal care and use Committee.
2.5 | Telomeric repeat amplification 
protocol (TRAP) assay
Telomerase activity was determined under recommended 
standard conditions of the TRAPEZE Telomerase Detection 
S7700 Kit (Millipore, Thermo Fisher Scientific) for telom-
eric repeat amplification (TRAP) using radioisotopic detec-
tion. Telomerase activity was determined in each sample 
using 0.5, 0.25, and 0.125 µg of protein extract and normal-
ized with the internal control included in the assay.27
2.6 | Real- time quantitative PCR
Total RNA from RLE- 6TN cells and animal tissues was ob-
tained using the TRIzol reagent (Invitrogen, Thermo Fisher 
Scientific, Waltham, MA, USA). RNA was converted to 
cDNA using random primers and the High- Capacity cDNA 
Archive Kit (Applied Biosystems, Thermo Fisher, Scientific 
Waltham, MA, USA). Quantitative PCR was made using 
the Power SYBR kit and the StepOne Plus Real- Time PCR 
System (both from Applied Biosystems). Relative expression 
levels were calculated using the comparative threshold cycle 
method36 and GAPDH as internal control. Oligonucleotides 
used are listed in Table  1. Rat IL6 and CDKN1A expres-
sion study was performed by using the TaqMan probes 
Rn01410330_m1 and Rn01427989_s1, respectively.
T A B L E  1  Primer sequence, 5′– 3′
Gene name Forward Reverse
TENASCIN- C ATGTTGAATGGCGACAC CGGTCTCCAAACCCAG
COLLAGEN I TGCTTGAAGACCTATGTGGGTA AAAGGCAGCATTTGGGGTAT
TGF- β1 AGAACCCCCATTGCTGTCCC GAAAGCCCTGTATTCCGTCTCC
FGF- 2 GAACCGGTACCTGGCTATGA CCGTTTTGGATCCGAGTTTA
TGF- βR- 1 AGAAAGCATCGGCAAAGGTC CCCAGGATATTTTCATGGCG
MCP- 1 CACCTGCTGCTACTCATTCACTG CTTCTTTGGGACACCTGCTGCT
PAI- 1 TGAGATCAGTACTGCGGACG GAGGGGCACATCTTTTTCAA
α- SMA AAGAGGAAGACAGCACAGCTC GATGGATGGGAAAACAGCC
VIMENTIN TGACCGCTTCGCCAACTA CGCAACTCCCTCATCTCCT
GADPH ACCACAGTCCATGCCATCAC TCCACCACCCTGTTGCTGTA
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2.7 | Lentiviral vector production and cell 
transduction
Lentiviral vector expressing GSE4 from the pRRL- CMV- 
IRES- EGFP vector were described in Ref. (29,30). Lentiviral 
vectors were produced using HEK 293T cells transfecting the 
pRRL- CMV- IRES- EGFP (empty or scramble vector) and 
expressing GSE4 (pRRL- CMV- GSE4- IRES- EGFP) together 
with pCD- NL- BH and pMD.2G VSV.G packaging plasmids. 
Seventy- two hours after transfection, supernatants were re-
covered and used to transduce cell lines in the presence of 
polybrene (5 µg/mL). Cell lines were characterized by meas-
uring expression of GSE4 RNA. Efficiency of expression 
was measured by evaluating EGFP expression by flow cy-
tometry. Experiments were carried out when the percentage 
of cells expressing GFP was higher than 85%.
2.8 | Nanoparticle synthesis and loading of 
scramble and GSE4 peptides
Chemically synthesized scramble and GSE4 peptide labeled 
with FITC were obtained from ChinaPeptides Co., Ltd. 
(Hangzhou, China) and purified by HPLC. PLGA/PEI na-
noparticle preparation and scramble and GSE4 loading were 
performed as previously described.31,32 Internalization effi-
ciency was estimated by determination of intracellular fluo-
rescence using a fluorescence ELISA reader.
2.9 | Micro- SPECT- CT
For SPECT/CT acquisition images, on days 0, 7, and 14; 
500  µCi of 99mTc- MAA (macroaggregated serum albumin, 
MAA) were injected in the tail vein. Thirty minutes after the 
administration; animals were anesthetized and introduced in 
multimodal acquisition equipment (Albira; Oncovision Gem- 
Imaging SA, Valencia, Spain). Previously, SPECT stud-
ies were programed with a field of view (FOV) of 80 mm, 
capture time 30  minutes, 60 projections per second, and a 
Pinhole collimator. And X- rays for CT acquisition were pro-
gramed with 400 uA intensity current, voltage 45 kV, and a 
filter attenuation of 0.5 mm; such intensity equivalent to an 
equivalent dose of 220 mSv and effective dose of 357.4 mSv. 
These doses are 20 times lower than reported LD50 dose
37 
30  minutes after the administration; animals were anesthe-
tized and introduced in multimodal acquisition equipment 
(Albira; Oncovision Gem- Imaging).
The images were reconstructed using the algorithm FBP 
(Filtered Back Projection) using the Standard parameters re-
construction Albira Suite 5.0 Reconstructor. The combina-
tion of acquisition and reconstruction result in a final image 
matrix 255 × 255 × 255 pixel size of 0.25 × 0.25 × 0.25 mm. 
The images were analyzed and quantified by Analysis 
software PMOD 3.2 (PMOD Technologies LTD, Zurich, 
Switzerland).
2.10 | Immunohistochemistry analysis
Formalin- fixed, paraffin- embedded lung tissue sections 
(5 µm) were de- waxed with Xylene and rehydrated through 
a series of alcohols to water. Antigen retrieval was per-
formed using an unmasking buffer pH 9 (10 mM Tris Base, 
1 mM EDTA Solution, 0.05% Tween 20) in a microwave 
oven for 20  minutes. Sections were blocked with a Goat 
Serum blocking solution (5% Goat serum, 1% BSA, 0.2% 
Triton- X- 100 in PBS pH 7.1) for 45  minutes, and then, 
incubated with primary antibodies at 4°C overnight in a 
humidity chamber. Primary antibodies used were: Dilution 
1:2000 rabbit anti- Pro- surfactant Protein- C, proSP-
 C (cat#AB3786 Millipore, Thermo Fisher Scientific, 
Waltham, MA, USA); Dilution 1:100 mouse monoclonal 
anti- Ki67 (cat# 550609 Becton Dickinson, Franklin Lakes, 
New Jersey, USA); Dilution 1:100 anti- Phospho- Histone 
H2A.X (Ser139), clone JBW301 (Cat# 05- 636 Millipore), 
anti- alfaSMA, clone 1A4 (cat# A5228 SIGMA) anti- TNFα 
(cat# SC52746 Santa Cruz Biotechnology, Dallas, Texas, 
USA). Sections were washed with PBS with 0.2%Triton- 
X- 100 and incubated with the secondary antibodies for 
45 minutes at room temperature. DAPI (D1306 Molecular 
Probes, Thermo Fisher, Scientific Waltham, MA, USA) or 
ToPro- 3 (T3605 Molecular Probes) was used for DNA nu-
clear staining and slides were then mounted using ProLong 
Diamond antifade reagent (P36970 Molecular Probes). 
All images were acquired using a LSM710 (Zeiss) confo-
cal microscope. All objectives were plan- apochromatic. 
Sequential scanning mode was used to avoid crosstalk 
between channels. All images correspond to a maximal 
projection and were processed with Zen2009 and Image J 
software for quantification. Quantification was performed 
determining the number of cells positive for a given an-
tibody among the total number of cells of each field, and 
counting at least ten fields. Specific normalization is indi-
cated in the legend of each figure.
2.11 | Trichromic acid, Picro Sirius 
Red, and H&E histochemistry
Tissues were fixed in 4% of buffered formalin, embedded 
in paraffin blocks, sectioned at 5 μm and stained using the 
standard hematoxylin- eosin (Sigma- Aldrich) (H&E) method 
and Masson trichrome, briefly; samples were deparaffinized 
and rehydrate through 100% alcohol, 95% alcohol 70% alco-
hol, then, incubated in Bouin's solution at 60°C for 1 hour and 
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washed in running tap water for 5 minutes. Then stained in 
Weigert's working hematoxylin (Merck) for 1 minute, rinsed 
in running warm tap water for 10 minutes, and a last wash 
with distilled water. After were stained in Biebrich scarlet- 
acid fuchsin solution for 2 minutes, rinsed in distilled water, 
differentiated in phosphomolybdic- phosphotungstic acid so-
lution for 15 minutes and 1% of acetic acid solution for 15 
minutes and washed in distilled water. For Sirius red colla-
gen staining, after deparaffinization and rehydration through 
100% alcohol, 95% alcohol 70% alcohol, incubated with 
Picro- Sirius Red solution and after washing, subjected to two 
changes in acidified water. All preparations were dehydrated 
through 95% of ethyl alcohol, absolute ethyl alcohol, and 
clear in xylene. Samples were analyzed under a light micros-
copy by two pathologists blind to the treatment. All images 
were acquired using the Axiophot microscope (Zeiss), a di-
rect microscope with transmitted light and epifluorescence 
(filters for DAPI, FITC and Red), using a DP70 (Olympus) 
color camera with the DP Controller image capture system. 
The objective used is a NEOFLUAR 40x objective. Image J 
was used to quantify the images, using color deconvolution 
to measure Picro- Sirius Red and Masson's Trichromic posi-
tive areas.
2.12 | Statistical analysis
For the statistical analysis of the results, the mean was taken 
as the measurement of the main tendency, while standard 
deviation (SD) was taken as the dispersion measurement. T- 
Student test was performed. The significance has been con-
sidered at *P < .05, ** for P < .01, and *** for P < .001. 
GraphPad Software v5.0 was used for statistical analysis and 
graphic representations.
3 |  RESULTS
3.1 | GSE4 inhibits DNA damage, IL6 
expression, and increases expression of TERC 
in bleomycin- treated RLE- 6TN cells
Bleomycin has been used as a profibrotic drug in animal 
models of lung fibrosis that nicely reproduces many aspects 
of the disease found in IPF patients. Bleomycin (Bleo) in-
duces pulmonary injury, inflammation, and subsequent 
fibrosis. In vitro Bleomycin induces DNA damage38 and 
expression of pro- inflammatory cytokines in lung cells. 
Based on that, we analyze the role of GSE4 expression in 
recovering the cell damage caused by bleomycin, by trans-
ducing the rat lung epithelial cell line RLE- 6TN, with len-
tiviral vectors expressing either scramble or GSE4 peptide 
(Figure S1A), and then, transduced cells were treated with 
different doses of bleomycin. First, telomerase activity was 
measured. Expression of GSE4 induced a significant increase 
of telomerase activity in bleomycin- treated cells (Figure 1A). 
Bleomycin did not affect telomerase activity, although 
higher doses of bleomycin reduced TERT gene expres-
sion (Figure 1B). RLE- 6TN cells expressing GSE4 showed 
higher expression levels of TERT and TERC as compared 
to scramble vector, even after increasing doses of bleomycin 
(Figure 1B and C). In basal conditions, treatment of RLE- 
6TN cells with GSE- PLGA/PEI nanoparticles also induced 
expression of TERT (Figure S1B) as previously described for 
other disease cell lines.28- 30,39 Together these results suggest 
that the increase in telomerase activity obtained in GSE4/
bleomycin- treated cells (Figure  1A) may be due to the in-
crease in TERT and TERC gene expression in response to the 
damage induced by bleomycin.
RLE- 6TN cells expressing scramble or GSE4 peptide 
when treated with increasing doses of bleomycin showed a 
dose- dependent increase of γ- H2A.X protein level that was in-
hibited by GSE4 expression (Figure 1D). Similar results were 
obtained treating RLE- 6TN cells with PLGA/PEI nanopar-
ticles loaded with scramble or GSE4 peptide (Figure S1C). 
We quantified the number of γ- H2A.X- associated foci per 
cell and found that GSE4 expression increased the number 
of cells with no- DNA damage at different bleomycin doses 
(Figure 1E and S1D). Further, we determined the number of 
telomere- associated foci (TIFs) and showed that GSE4 ex-
pression induced a small but statistically significant decrease 
of DNA damage at telomeres (Figure S2A and B) as described 
previously in other disease models.28,30 Finally, we analyzed 
the DNA damage response by determining the activation of 
p53 by phosphorylation at serine15. We found an increase in 
p53 phosphorylation after bleomycin treatment that was at-
tenuated in cells expressing GSE4 (Figure 2A). Accordingly, 
expression of CDKN1A also increased in a dose- dependent 
manner with bleomycin and this was also attenuated at the 
higher doses of bleomycin (Figure 2B). On the contrary, we 
did not detect differences in p16 expression in bleomycin- 
treated cells (not shown). When we analyzed the inflamma-
tory response to bleomycin, we observed a reduction of IL- 6 
gene expression in GSE4 expressing cells compared to con-
trols, were IL- 6 was induced at any of the bleomycin doses 
tested (Figure  2C). This result was confirmed with GSE4- 
loaded nanoparticles, indicating that GSE4 was able, in vitro, 
to abolish the activation of bleomycin- induced expression of 
inflammation mediators (Figure S3).
Expression of pro- inflammatory cytokines is also in-
volved in the activation of p38 MAPK.30,40 We have found 
an increase in p38 phosphorylation in scramble cells with in-
creasing concentrations of bleomycin that was not observed 
in GSE4- expressing cells (Figure 2D). Persistent activation of 
p38 MAPK is involved in apoptosis induction in response to 
DNA damaging agents.41 Our data showed that the increased 
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ratio of cleaved- caspase 3/caspase 3 induced by bleomycin 
was reduced by GSE4 expression (Figure 2E) suggesting in-
hibition of apoptosis by this peptide.
3.2 | GSE4 inhibits the expression of TGF- 
β- induced genes in RLE- 6TN cells
Since TGF- β is the most relevant profibrotic cytokine and with 
a relevant role in pulmonary fibrosis,25,26 we studied the effect 
of TGF- β treatment in the expression of profibrotic genes in 
RLE- 6TN cells. TGF- β treatment of RLE- 6TN cells induces 
the expression of many genes related to the fibrotic phenotype 
(Figure 3) including α- smooth muscle actin (α- SMA), fibroblast 
growth factor (FGF- 2), TGF- β receptor 1 (TGF- βR- 1), vimen-
tin, monocyte chemoattractant protein (MCP1), plasminogen 
activator inhibitor (PAI- 1), TGF- β1, and collagen type I and 
III. GSE4 expression in rat AECs treated with TGF- β resulted 
in decreased expression levels of all these genes (Figure 3). We 
also observed that in the absence of TGF- β expression of GSE4 
is also able to inhibit the expression of α- SMA, FGF2, and 
collagen type I and III as compared to control cells. Together 
these data indicated that GSE4 is able to inhibit the profibrotic 
response induced by TGF- β in rat AECs.
3.3 | In vivo treatment with 
GSE4- nanoparticles reduced lung 
damage and fibrosis
We used a rat model of intratracheal bleomycin- induced 
lung fibrosis in order to explore if treatment with 
F I G U R E  1  GSE4 expression increases telomerase activity and decreases DNA damage in bleomycin- treated RLE- 6TN cells. A, Telomerase 
activity in RLE- 6TN cells treated with bleomycin. RLE- 6TN cells expressing scramble (SCR) or GSE4 peptides were treated with bleomycin 
(Bleo 2.5 µg/mL) for 6 hours when indicated. Telomerase activity was determined using the TRAP assay kit. Different extract dilutions were done 
for each sample (right panels). Telomerase activity was quantified and normalized by the internal control of amplification (arrow) of the kit and 
represented as relative activity (left panel). Data points represent the mean and standard deviations of two experiments performed in triplicate. 
The activity of non- transfected cells transfected was considered as 100% and all the others referred to that one. Asterisks indicated the statistical 
significance (* P < .05, **P < .01, ***P < .001). B and C, Expression levels of TERT (B) and TERC (C) in RLE- 6TN cells expressing either 
scramble (SCR) or GSE4 peptides and treated with bleomycin at the indicated concentrations for 6 hours. RNA was extracted and the expression of 
TERT and TERC measured by RT- q- PCR and data normalized with GADPH expression and referred to untreated RLE- 6TN SCR cells. Asterisks 
indicated the statistical significance (* P < .05, **P < .01, ***P < .001). D, RLE- 6TN cells expressing scramble (SCR) or GSE4 peptides were 
treated with bleomycin at the indicated concentrations for 6 hours. Cells were lysed and the presence of γ- H2A.X and α- tubulin (loading control) 
analyzed by western blot (Left panel). Quantification values indicate the estimated ratio between γ- H2A.X and α- tubulin expression levels referred 
to those found in control RLE- 6TN SCR cells. E, Quantification of γ- H2A.X- associated foci in RLE- 6TN cells expressing either scramble (SCR) 
or GSE4. At least 200 cells were analyzed in each cell line and the number of foci/cell (among the total number of cells in the field) was divided 
into three groups. The number of cells in each group is indicated. Asterisks indicate significant differences between cell lines. Average values and 
standard deviations of two independent experiments are shown. Asterisks indicated the statistical significance (* P < .05, **P < .01, ***P < .001)
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GSE4- nanoparticles was able on the first place to target lung 
cells and second to reduce lung damage and fibrosis in a 
more physiological model. Consequently, to test if GSE4 was 
able to target lung cells, we first performed a short treatment 
of rats by intraperitoneal inoculation of GSE4- nanoparticles 
24 hours after the intratracheal bleomycin instillation. Three 
days later, we sacrificed the animals to test the effect of GSE4- 
nanoparticles treatment in the lungs. First, lung proteins were 
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extracted from one lung and telomerase activity was meas-
ured. Our results showed that there was an increase (20%) 
in telomerase activity in rats treated with GSE4 compared 
with control lungs and this increased activity was sustained in 
lungs treated with bleomycin plus GSE4 (Figure 4A). In the 
other lung, we analyzed the expression of γ- H2AX in the pro- 
surfactant protein C positive (proSP- C) cells to determine if 
there was an inhibition of DNA damage by the expression in 
GSE4 in rat alveolar type II cells. We found that treatment 
with bleomycin increased the number of proSP- C positive 
cells expressing γ- H2A.X protein, and the number of posi-
tive cells decreased to levels similar to control cells when the 
rats were inoculated with GSE4- nanoparticles (Figure 4B), 
suggesting that GSE4 protects proSP- C cells from bleomycin 
treatment. In order to test if treatment with bleomycin was 
inducing fibrosis, we analyzed expression of the profibrotic 
marker α- SMA. The results indicated that there was an in-
crease in the number of cells expressing α- SMA in the lungs 
of bleomycin- treated rats up to fourfold (Figure 4C) with re-
spect to control lungs and this short GSE4 treatment slightly 
reduced it, indicating a decrease in myofibroblast- cell num-
ber. These results indicated that GSE4- nanoparticles were 
able to reach the lungs of the treated rats and reproduce an 
increase in telomerase activity observed on vitro even after 
bleomycin treatment and also to decrease DNA damage in 
proSP- C cells.
Using the same pulmonary fibrosis animal model, we 
studied the effect of GSE4- nanoparticles in two different 
protocols of treatment. In the preventive approach, rats were 
inoculated with GSE4- nanoparticles 1 day before the bleo-
mycin treatment. For the therapeutic protocol, we inoculated 
GSE4- nanoparticles in rats 5 days after the bleomycin treat-
ment when inflammatory/fibrotic process has already started. 
In both models, the injections of nanoparticles continued 
every 4  days until the end of the experiment (Figure  5A). 
We included three groups of rats for each protocol; untreated 
control, bleomycin, and bleomycin plus GSE4- nanoparticles 
inoculations. Rats were euthanized at day 14 since in our pre-
vious studies, we observed that fibrosis was already estab-
lished at that time after bleomycin administration.42
Lung damage was determined in animals from both proto-
cols by using CT scan (Figure 5B left panel) and histology at 
the end of the experiments. Figure 5C shows the quantitative 
representation of the CT images as density values (Hounsfield 
units (HU units)). For this quantification, we selected a vol-
ume of interest (VOI) that includes the whole lung. HU val-
ues correspond to the density of tissue, where values ranging 
from −1000 HU correspond to the air density and + 1000 
HU to the bone density (Figure 5B, right panel). Quantitative 
analysis of the bleomycin group showed an increase in HUs 
by day 7 compared to controls (−300 to −175 for both pro-
tocols), corresponding to the inflammatory peak (Figure 5B 
and C) that persisted decreasing until day 14 (−275 to −75 
preventive protocol and −300 to −125 therapeutic protocol) 
indicating the presence of fibrotic tissue. The administration 
of GSE4- nanoparticles was able to restrict the decrease of HU 
produced by bleomycin treatment in both experimental pro-
tocols (−300 to −220 preventive protocol and −300 to −250 
therapeutic protocol at 14 days) (Figure 5B and C). At day 
14, the control group exhibited no morphological alterations 
(Figure 5B), while the bleomycin group presented decreased 
lung volume due to the destruction of lung parenchyma and 
we observed the appearance of ground- glass opacities. CT 
image showed reduction of lung- damaged areas in the GSE4- 
nanoparticles- treated group (Figure 5B CT images). The ten-
dency observed in the CT images was confirmed with SPECT 
acquisition by measuring 99mTc- MAA (microalbumin) distri-
bution. We quantified 99mTc- MAA distribution images using 
F I G U R E  2  GSE4 decreases bleomycin- dependent expression of IL6, activated p38, and caspase 3 activity in RLE- 6TN cells. A, Expression of 
Pp53 in RLE- 6TN cells treated with bleomycin RLE- 6TN cells expressing SCR or GSE4. Cells were lysed and the protein extracts used for western 
blot analysis of p53 phosphorylated at serine15 (Pp53) expression using a specific antibody and also with α- tubulin antibody as loading control 
(left panel). The ratio between the expression detected by both antibodies is indicated in the graphic at right, using RLE- 6TN SCR cells as control. 
B, Expression of CDKN1A in RLE- 6TN cells treated with bleomycin. RLE- 6TN cells expressing scramble (SCR) or GSE4 peptides were treated 
with bleomycin at the indicated concentrations for 6 hours and total RNA extracted. The expression level of CDKN1A was estimated by RT- q- 
PCR with specific primers and β- actin expression used to normalize data. Expression was referred to untreated RLE- 6TN SCR cells and represents 
data sets of three independent experiments. Asterisks indicated the statistical significance (* P < .05, **P < .01, ***<0.001). C, Expression of 
IL- 6 in RLE- 6TN cells treated with bleomycin. RLE- 6TN cells expressing scramble (SCR) or GSE4 peptides were treated with bleomycin at the 
indicated concentrations for 6 hours and total RNA extracted. The expression level of IL- 6 was estimated by RT- q- PCR with specific primers and 
β- actin expression used to normalize data. Expression was referred to untreated RLE- 6TN SCR cells and represents data sets of three independent 
experiments. Asterisks indicated the statistical significance (* P < .05, **P < .01, ***<0.001). D, Expression of phosphorylated p38. RLE- 6TN 
cells expressing SCR or GSE4 were lysed and the protein extracts used for western blot analysis of phospho- p38 expression using a specific 
antibody and also with a p38 antibody as loading control (upper panel). The ratio between the expression detected by both antibodies is indicated 
in the graphic bellow, using RLE- 6TN SCR cells as control. The experiments were repeated three times with similar results. C) Caspase 3 activity. 
RLE- 6TN cells expressing SCR or GSE4 were lysed and the protein extracts used for western blot analysis of caspase 3 expression, both the intact 
protein (caspase 3) and the products of activation (cleaved caspase 3) by using a specific antibody (upper panel). The ratio between expression 
detected by cleaved- caspase 3 and caspase 3 is indicated in the figure bellow using RLE- 6TN SCR cells as control. A representative experiment is 
presented. The experiments were repeated three times with similar results
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the therapeutic protocol (Figure 5E). The results showed an 
increase in the 99mTc uptake that in bleomycin group was di-
minishing as the disease progressed (day 0 to day 7), but the 
uptake in the bleomycin- GSE4- treated group was similar to 
bleomycin untreated controls, indicating that treatment with 
GSE4- nanoparticles normalized the intake of 99mTc, inhib-
ited by bleomycin. In addition, we monitored the weight of 
the rats in both treatment protocols (Figure S4) and found that 
there is weight loss in rats treated with bleomycin at 14 days 
(8%) that is partially recovered when rats were treated with 
bleomycin + GSE4. Similar results were obtained for both 
preventive and therapeutic protocols.
Two- blinded independent pathologist examined the lung 
parenchymal lesions and accumulation of collagen in lung 
sections from different groups (Figure  S5). Collagen was 
measured by both Mason´s Trichrome and Sirius red histolog-
ical staining and that was quantified in the four experimental 
groups of rats. The control and GSE4- treated lungs showed 
F I G U R E  3  Expression of GSE4 inhibits the expression of TGF- β/fibrotic genes in RLE- 6TN cells. RLE- 6TN cells expressing scramble 
(SCR) or GSE4 peptides were treated when indicated with TGF- β (5 ng/mL) for 48 hours. Total RNA was extracted and the expression levels of 
the indicated genes estimated by RT- q- PCR with specific primers (Table 1). Data were normalized to GAPDH expression levels and are shown 
as mean ± SD of three independent experiments. Relative mRNA levels were normalized for those of scramble cell line (SCR) without TGF- β 
treatment. Asterisks indicated the statistical significance (* P < .05, **P < .01, ***P < .001)
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F I G U R E  4  GSE4- nanoparticles recover telomerase activity and inhibit DNA damage at proSP- C cells in bleomycin- treated rats. A, 
Telomerase activity in lungs of GSE4- treated rats. Wistar rats were intratracheally instilled with a single dose of bleomycin (Bleo) 24 hours after 
being inoculated intraperitoneally once with GSE4- nanoparticles. Three days later one lung was used for TRAP assays. Twenty- four rats were 
used for each experiment and divided into four groups: control (n = 4), GSE4 (n = 4), Bleo (n = 8), and Bleo + GSE4 (n = 8). Different amounts 
of extracts were used for each TRAP assay (upper panel). Quantification of the intensity of the bands (TEL) in relation with the internal control 
(IC) (arrow) (TEL/IC) is presented (right panel). The experiments were repeated three times with similar results and average values and standard 
deviations of representative experiment showed (lower panel). Asterisks indicated the statistical significance (* P < .05, **P < .01, ***P < .001). 
B, DNA damage in proSP- C + cells in GSE4- treated rats. One of the lungs isolated in A was used for immunohistochemistry detection of γ- 
H2A.X- associated foci and co- localization with proSP- C in each cell. The co- localization of both antigens was expressed as the percentage from 
total number of cells in 10 different fields for each analyzed lung. Right panel. C, Lungs from the experiment described in B) were subjected to 
immunohistochemistry to determine the expression of α- SMA (pink) and DAPI (blue). An insert for each picture showing amplified images is 
presented. The number of cells positive for α- SMA was determined in 10 different fields/rat and represented as the percentage of the total cell 
number per field. Asterisks indicated the statistical significance (* P < .05, **P < .01, ***P < .001)
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morphologically normal tissue with weak stain for collagen 
(Figure S5B and S5C). The bleomycin- treated group showed 
a clear interstitial alveolar involvement and collagen staining 
in fibrotic areas and parenchyma and increased expression 
of collagen. In contrast, the Bleo/GSE4- lungs showed that 
parenchymal architecture was better preserved, mild areas of 
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inflammatory infiltration were detected, and a statistically 
significant decrease in the collagen content was detected by 
both histological methods. These results indicated that the 
treatment with GSE4- nanoparticles in bleomycin- treated rats 
was able to protect from the massive cellular damage induced 
by bleomycin (Figure 5 and S5).
We also studied the expression levels of some pro- 
inflammatory cytokines such as IL6 and MCP1, whose ex-
pression was reduced by in vitro treatment or expression of 
GSE4 in RLE- 6TN cells (Figures 2C, 3, and S3). We found 
that the expression levels of these two cytokines increased 
in lungs treated with bleomycin, and an important de-
crease in those rats treated with Bleo + GSE4 resembling 
the in vitro results (Figure  S6A). Further, expression of 
TNF- α was also studied by immunohistochemistry and we 
found that treatment of rats with GSE4 already decreased 
a small basal expression of this cytokine (Figure  S6B). 
Bleomycin induces an important increase and finally in 
Bleomycin + GSE4- treated rats, its expression is reduced 
by 50% (Figure S6B).
Next, we quantified the expression of proSP- C in order 
to investigate the damage and/or recovery of type II alveo-
lar epithelial cells by GSE4 nanoparticles. We observed that 
bleo + GSE4- treated lungs showed an enrichment of 40% in 
multicellular alveoli- like structures (ranging from 2 to 5 cells 
per structure) expressing proSP- C when compared to the 
other treated groups (Figure 6A). This suggested that there 
was an increase in the number of proSP- C+ cells induced by 
GSE4. To check if this correlated with an increase in cell 
proliferation of proSP- C cells, we tested the co- localization 
of Ki- 67 and proSP- C in the lungs of the different groups. 
The results indicated that there was an increase in the num-
ber of Ki- 67/proSP- C co- expressing cells when rats were 
treated with GSE4 alone, but interestingly increased more in 
Bleo + GSE4 rats (4,5%) (Figure 6B). We also studied the ex-
pression of the fibrotic marker α- SMA. The results indicated 
that there was an increase in the number of cells expressing 
α- SMA in the lungs of bleomycin- treated rats up to 10- fold 
(Figure 6C) and GSE4 treatment reduced to 5- fold indicating 
a decrease in myofibroblasts- cell number. Taken together, 
these results suggest that treatment with GSE4- nanoparticles 
after bleomycin resulted in an improvement of the lung re-
pair capacity supported by the decrease in collagen content, 
fibrotic biomarkers, DNA damage, increased DNA synthesis, 
and a decrease in cytokine expression, and remarkably these 
results support also those obtained in the in vitro cell models.
4 |  DISCUSSION
Idiopathic pulmonary fibrosis (IPF) occurs in genetically 
susceptible aged individuals exposed to several environ-
mental risk factors.8,12 In agreement with this observation 
in one- fourth of the cases this disease is associated with tel-
omere shortening, which would impair lung stem cell func-
tion17,20,43,44 and tissue repair.
Here, we describe that expression of GSE4 peptide in 
rat AECs reverts many of the pathological changes induced 
by bleomycin. Expression of GSE4 induced an important 
increase in telomerase activity. This activation on telo-
merase seems to be a consequence of increased expression 
of TERT and TERC genes in GSE4 expressing cells. We 
have also observed a decrease in DNA damage and DNA 
damage signaling in GSE4- RLE- 6TN cells after bleomy-
cin treatment. These results suggested that expression of 
GSE4 protects rat AECs from the bleomycin- induced 
damage. Similar results have been observed in response to 
DNA damage in other disease models such as dyskeratosis 
congenita (DC)29,39 and ataxia telangiectasia (AT)30 cells. 
More interestingly, DNA damage induced in telomeres 
by bleomycin is also slightly decreased by expression of 
GSE4, as already reported by expression of a similar pep-
tide GSE24.2 in DC cells.39
Bleomycin also induced an increase in IL6 expression in 
RLE- 6TN cells as already described for cells with persistent 
DNA damage.30,45 Expression of GSE4 decreased IL6 ex-
pression in bleomycin- treated cells. Increased expression of 
this cytokine in AEC cells is involved in the inflammatory 
pathways that ultimately trigger a fibrotic process46 and is 
also involved in the activation of p38 MAPK activity.40 In 
F I G U R E  5  Bleomycin- induced fibrosis is attenuated by GSE4- loaded nanoparticles. A, Experimental design of preventive and therapeutic 
protocols. Bleomycin was intratracheally instilled at time 0 (upper arrow) while nanoparticles beginning at day −1 (preventive protocol) or 5 
(therapeutic protocol) as indicated in the lower part of de diagram, later on, nanoparticles were inoculated intraperitoneally every 4 days. B, The 
Hounsfield scale (HS) and CT images. Upper panel HS of tissue density values: air as −1000 HU (minimum HU value), lung, fat, water (0 HU), 
soft tissue, and bone (+1000 HU). Lower panel representative SPECT acquisition images of rats subjected to CT scan of the lungs at day 14 
after bleomycin instillation. Experimental groups correspond to rats: not treated (control, n = 4), bleomycin treated (Bleo, n = 8)) of bleomycin 
and GSE4 nanoparticles treated (Bleo + GSE4, n = 8)). C, Quantitative representation of CT technique in HS of the values of rat lungs of the 
preventive and therapeutic model from images taken at day 0, 7, and 14. Asterisks indicated the statistical significance (* P < .05, **P < .01, 
***P < .001). D, Images of 99mTc- MAA distribution in rats subjected to the therapeutic protocol. SPECT/CT acquisition images, on days 0 
and 7; Images were analyzed and quantified by Analysis software PMOD 3.2. Experimental groups are Control, Bleomycin, and Bleo + GSE4. 
Representative images are presented. E, Quantification of images obtained in D (four rats/group), considering the radionuclide volume/total lung 
volume ratio. The data at experimental group at day 7 are referred to day 0. Asterisks indicated the statistical significance (* P < .05, **P < .01, 
***P < .001)
14 of 18 |   PINTADO- BERNINCHES ET Al.
F I G U R E  6  Treatment with GSE4- nanoparticles inhibits DNA damage in alveolar cells and decreases α- SMA expression. A, Right panel. 
Lungs from rats from each one of the therapeutic experimental groups: control (n = 4), GSE4 (n = 4), Bleo (n = 8), and Bleo + GSE4 (n = 8) were 
fixed and subjected to immunohistochemistry to determine the number of alveolar type II cells using proSP- C- specific antibody (green), nuclei 
were stained with DAPI (blue). An insert for each picture showing amplified images is presented. The number of pro- SPC+ cells was determined 
in 10 different fields/rat and the number of pro- SPC+ cells by alveolar structure determined. The data were grouped depending on the number of 
pro- SPC+ cells per structure among the total structures in the field: 1, 2- 4, and >5 as shown in left panel. B, Right Lungs from the experiment 
described in (A) were subjected to immunohistochemistry to determine the expression of Ki- 67 (pink), proSP- C (green), and DAPI (blue). An 
insert for each picture showing amplified images is presented. The percentage of cells co- expressing Ki- 67 and proSP- C (SPC) among the total cell 
number per field in 10 different fields/rat is represented in left panel. C, Right panel. Lungs from the experiment described in (A) were subjected 
to immunohistochemistry to determine the expression of α- SMA (pink) and DAPI (blue). An insert for each picture showing amplified images 
is presented. The number of cells positive for α- SMA was determined in 10 different fields/rat and represented as the percentage of the total cell 
number per field. For all panels, asterisks indicated the statistical significance (*P < .05, **P < .01, ***P < .001)
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GSE4- RLE- 6TN cells treated with bleomycin, the ratio of 
p38 activated/unphosphorylated p38 decreased in contrast to 
scramble- RLE- 6TN cells. Bleomycin also increased apopto-
sis in RLE- 6TN cells, in agreement with the described induc-
tion of apoptosis in pneumocytes of fibrotic animal models.45 
Expression of GSE4 in bleomycin- treated RLE- 6TN cells de-
creases apoptosis. These results strongly indicated that GSE4 
would counteract the cellular and DNA damage that is initi-
ated by bleomycin in this cellular model.
One of the relevant cytokines in the fibrotic process in 
the lung is TGF- β, that contributes to change the expression 
of genes responsible for the epithelial to mesenchymal tran-
sition (EMT) that lead to fibrosis.47 TGF- β- induced distur-
bances of the homeostatic microenvironment are critical to 
promote cell activation, migration, invasion, or hyperplastic 
changes.47 In addition, excessive extracellular matrix pro-
duction contributes in a major way to disease pathogenesis. 
Because of the relevance of TGF- β in lung fibrosis, the pos-
sible role of GSE4 on TGF- β- induced fibrosis in RLE- 6TN 
cells was studied next. Interestingly, we found that expression 
of GSE4 in RLE- 6TN cells decreased expression of genes 
involved in EMT. Moreover, GSE4 was also able to atten-
uate their induction in response to TGF- β, including those 
of COL1 and COL3 genes. These results agreed with others 
described for compounds with anti- fibrotic activity such as 
pirfenidone48 or nintedanib.49
Type I and II pneumocytes are the major targets for lung 
damage in IPF. In a rat IPF model induced by bleomycin, in-
oculation of GSE4- nanoparticles rescued telomerase activity 
and decreased DNA damage in proSP- C cells confirming that 
GSE4- nanoparticles are active in these cells and would be 
suitable for in vivo treatment in a fibrosis model since they 
reach critical cells in the disease. We did not measure telo-
mere length changes since the experiments were too short to 
produce them. Instead, we measure telomerase activity, de-
scribing an upregulation in GSE4- treated tissues that would 
be likely involved in protection from DNA damage induced 
by bleomycin. Increased DNA damage has been observed in 
explanted IPF lungs obtained from transplant surgeries com-
pared to controls.26 Further, increased p21 expression as a 
hallmark of aging and DNA damage has been reported in pul-
monary fibrosis.2 Our data demonstrates that treatment with 
GSE4 could prevent this feature.
Preventive and therapeutic protocols with GSE4- 
nanoparticles in rats treated with bleomycin showed 
promising results. In both situations, treatment with GSE4- 
nanoparticles was able to prevent and interfere with the lung 
damage induced by bleomycin as shown by the analyses of 
CT images obtained in the treated rats. Lung capacity also 
showed an improvement as assayed by the albumin 99mTc- 
MAA lung distribution. We also detected a decrease in ex-
pression pro- inflammatory cytokines such as IL6, MCP1, 
and TNF- α, besides collagen by GSE4. The expression of 
proSP- C in the lungs was used to determine alveolar struc-
tures containing more than two proSP- C cells. The results 
obtained suggested increased repair of alveolar structures in-
duced by GSE4- nanoparticles. Additionally, this correlated 
with increased number of proliferative proSP- C cells. Finally, 
this treatment also inhibited the expression of the fibrotic 
marker α- SMA, further supporting that GSE4- nanoparticles 
protected proSP- C cells from the damage induced by bleomy-
cin. PLGA nanoparticles have been used as an FDA approved 
delivery system for different drugs.50 In addition, PLGA ap-
proved nanoparticles loaded with pirfenidone have previously 
been used in preclinical mice models of bleomycin- induced 
pulmonary fibrosis showing an anti- fibrotic activity.51,52 This 
together with the evidence presented in this manuscript sug-
gests that treatment with PLGA- GSE4- loaded nanoparticles 
would be a potential anti- fibrotic option for patients with lung 
fibrosis.
The only tested treatment for telomere diseases, like DC 
and IPF, is Danazol, which stimulates the estrogen- element 
at TERT promoter.53,54 Although the results were promising, 
long- term treatments with this sexual hormone can have ad-
verse side effects such as hepatic toxicity, lipid abnormali-
ties, muscle problems, and of course the masculinization in 
women treated with this therapy, and as a consequence is 
not currently used.54 In addition, it has been suggested that 
extrapulmonary alterations in other cell types, like the bone 
marrow mesenchymal stem cells (B- MSCs) from IPF pa-
tients, that have a premature senescence phenotype, might 
contribute to the pathogenesis of the disease. Moreover, it 
was demonstrated that infusion of B- MSCs isolated from 
normal young donors in the initial stages of the injury results 
in a decrease in collagen deposition in the lungs after bleo-
mycin instillation and milder fibrosis.55 Since GSE4 is able 
to increase telomerase activity, decrease DNA damage and 
induce survival in lymphoblasts derived from DC patients,29 
it is tempting to suggest that GSE4 could improve the bene-
ficial activity of B- MSCs. In the same line, it would be inter-
esting to investigate the use of GSE4 in lung fibrosis patients 
with short telomeres, since besides helping to recover lung 
damage would also contribute to overcome the blood abnor-
malities found in these patients without the side effects of the 
anti- fibrotic therapies.56
There are limitations in our current study. We have used 
a lung fibrosis model, using bleomycin as a fibrotic inducer 
that does not recapitulate some features of IPF pathology 
such as mortality. This could be due to the partial reversibil-
ity of the injure at later timepoints and to the lack in alter-
ations in other cells types (B- MSC), so it may not represent 
the complexity of the disease. Still, approved treatments for 
IPFs such as pirfenidone and nintedanib, were tested in this 
model since is the only existing one. On the contrary, we need 
to develop genetic mice models to induce GSE4 in specific 
cell types, such as alveolar type II cells and compare it to the 
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expression in lung fibroblasts to define its cell type- specific 
functions. Further, it would be interesting to assay if treat-
ment with GSE4- nanoparticles would have impact on IPF 
induced in a short telomere mice model.
Altogether, the results presented here demonstrate that 
treatment of lung damage induced by bleomycin with GSE4- 
nanoparticles, decreases DNA damage, activates telomerase 
activity, decreases inflammation, apoptosis, and EMT, result-
ing in a decreased lung fibrosis, and increased number of al-
veolar cells. No deleterious, but beneficial effects have been 
observed by GSE4 treatment in different disease- derived cell 
models (DC, AT), in contrast to the toxicity observed in the 
actual IPF treatments that in addition have limited beneficial 
effects. Therefore, the use of GSE4- nanoparticles should be 
considered and more deeply explored as an alternative treat-
ment for lung fibrotic patients.
ACKNOWLEDGMENTS
R.P laboratory was funded by grants P17- 01401 (Fondo 
de Investigaciones Sanitarias, Instituto de Salud Carlos 
III, Spain supported by FEDER funds), CIBER 576/805_
ER16PE06P2016 and MINECO from the Spanish Government 
(INNPACTO, IPT- 2012- 0674- 090000). M.M- M. laboratory 
was funded by Instituto de Salud Carlos III PI18/00367, sup-
ported by FEDER (Fondos Europeos de Desarrollo Regional 
(a way to build Europe)), JC received funds from MINECO 
CICYT SAF2014- 55322- P, and GG laboratory was funded 
by grant SAF2015- 68073- R (MINECO/FEDER) supported 
by FEDER funds. C.MG and R G- L are granted by the 
CIBERER. We gratefully acknowledge to CNB IIB histol-
ogy Monica Martin Belinchón for technical assistance in the 
microscopy core facility and Ana Sastre- Perona for helpful 
comments about the manuscript.
AUTHOR CONTRIBUTIONS
RP, LS, and MM- M conceived and designed research and 
wrote the paper. JC and AS performed research rat in vivo 
studies and processed all the image data. LP- B, AM- W, BF- 
V, R G- L, and LP- B performed most in vitro work. GG con-
tributed with the vectors used in the cell assays. CM- G and 
EG- AS performed research processed the in vivo samples for 
immunohistochemistry. LI, SPE, RMH, MI, and JLP, per-
formed research obtained and characterized the PLGA/PEI 
nanoparticles. All authors critically revised the manuscript 
for important intellectual content.
ORCID
Rosario Perona   https://orcid.org/0000-0002-2973-5153 
REFERENCES
 1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/
ALAT statement: idiopathic pulmonary fibrosis: evidence- based 
guidelines for diagnosis and management. Am J Respir Crit Care 
Med. 2011;183:788- 824.
 2. Selman M, Pardo A. Revealing the pathogenic and aging- related 
mechanisms of the enigmatic idiopathic pulmonary fibrosis. an in-
tegral model. Am J Respir Crit Care Med. 2014;189:1161- 1172.
 3. Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. 
Prednisone, azathioprine, and N- acetylcysteine for pulmonary fi-
brosis. N Engl J Med. 2012;366:1968- 1977.
 4. Ng B, Dong J, D'Agostino G, et al. Interleukin- 11 is a thera-
peutic target in idiopathic pulmonary fibrosis. Sci Transl Med. 
2019;11(511):eaaw1237. https://doi.org/10.1126/scitr anslm ed. 
aaw1237
 5. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of 
nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 
2014;370:2071- 2082.
 6. King TE Jr, Bradford WZ, Castro- Bernardini S, et al. A phase 3 
trial of pirfenidone in patients with idiopathic pulmonary fibrosis. 
N Engl J Med. 2014;370:2083- 2092.
 7. Mora AL, Rojas M, Pardo A, Selman M. Emerging therapies for 
idiopathic pulmonary fibrosis, a progressive age- related disease. 
Nat Rev Drug Discov. 2017;16:810.
 8. Armanios M, Blackburn EH. The telomere syndromes. Nat Rev 
Genet. 2012;13:693- 704.
 9. Konigshoff M. Lung cancer in pulmonary fibrosis: tales of epithe-
lial cell plasticity. Respiration. 2011;81:353- 358.
 10. Povedano JM, Martinez P, Serrano R, et al. Therapeutic effects of 
telomerase in mice with pulmonary fibrosis induced by damage to 
the lungs and short telomeres. Elife. 2018;7:e31299.
 11. Naikawadi RP, Disayabutr S, Mallavia B, et al. Telomere dysfunc-
tion in alveolar epithelial cells causes lung remodeling and fibrosis. 
JCI Insight. 2016;1:e86704.
 12. Perona R, Iarriccio L, Pintado- Berninches L, et al. Molecular di-
agnosis and precision therapeutic approaches for telomere biology 
disorders. In: M. L. Larramendy (Ed.), Telomere— A complex end 
of a chromosome. Intech; 2016:77- 117.
 13. Stanley SE, Gable DL, Wagner CL, et al. Loss- of- function muta-
tions in the RNA biogenesis factor NAF1 predispose to pulmonary 
fibrosis- emphysema. Sci Transl Med. 2016;8:351ra107.
 14. Hoffman TW, van der Vis JJ, van der Smagt JJ, Massink MPG, 
Grutters JC, van Moorsel CHM. Pulmonary fibrosis linked to vari-
ants in the ACD gene, encoding the telomere protein TPP1. Eur 
Respir J. 2019;54(6):1900809.
 15. Kannengiesser C, Manali ED, Revy P, et al. First heterozygous 
NOP10 mutation in familial pulmonary fibrosis. Eur Respir J. 
2020;55(6):1902465.
 16. Benyelles M, O'Donohue MF, Kermasson L, et al. NHP2 defi-
ciency impairs rRNA biogenesis and causes pulmonary fibro-
sis and H√∏yeraal- Hreidarsson syndrome. Hum Mol Genet. 
2020;29:907- 922.
 17. Hoffman TW, van Moorsel CHM, Borie R, Crestani B. Pulmonary 
phenotypes associated with genetic variation in telomere- related 
genes. Curr Opin Pulm Med. 2018;24:269- 280.
 18. Liu YY, Shi Y, Liu Y, Pan XH, Zhang KX. Telomere shortening 
activates TGF- beta/Smads signaling in lungs and enhances both li-
popolysaccharide and bleomycin- induced pulmonary fibrosis. Acta 
Pharmacol Sin. 2018;39:1735- 1745.
 19. Stanley SE, Chen JJ, Podlevsky JD, et al. Telomerase mutations 
in smokers with severe emphysema. J Clin Invest. 2015;125: 
563- 570.
   | 17 of 18PINTADO- BERNINCHES ET Al.
 20. Chen R, Zhang K, Chen H, et al. Telomerase deficiency causes 
alveolar stem cell senescence- associated low- grade inflammation 
in lungs. J Biol Chem. 2015;290:30813- 30829.
 21. Willis BC, Borok Z. TGF- beta- induced EMT: mechanisms and im-
plications for fibrotic lung disease. Am J Physiol Lung Cell Mol 
Physiol. 2007;293:L525- 534.
 22. Willis BC, duBois RM, Borok Z. Epithelial origin of myofibroblasts 
during fibrosis in the lung. Proc Am Thorac Soc. 2006;3:377- 382.
 23. Willis BC, Liebler JM, Luby- Phelps K, et al. Induction of epithelial- 
mesenchymal transition in alveolar epithelial cells by transforming 
growth factor- beta1: potential role in idiopathic pulmonary fibro-
sis. Am J Pathol. 2005;166:1321- 1332.
 24. Antoniades HN, Bravo MA, Avila RE, et al. Platelet- derived 
growth factor in idiopathic pulmonary fibrosis. J Clin Invest. 
1990;86:1055- 1064.
 25. Khalil N, O'Connor RN, Flanders KC, Unruh H. TGF- beta 1, but 
not TGF- beta 2 or TGF- beta 3, is differentially present in epithe-
lial cells of advanced pulmonary fibrosis: an immunohistochemical 
study. Am J Respir Cell Mol Biol. 1996;14:131- 138.
 26. Goldmann T, Zissel G, Watz H, et al. Human alveolar epithe-
lial cells type II are capable of TGFbeta- dependent epithelial- 
mesenchymal- transition and collagen- synthesis. Respir Res. 
2018;19(1):138.
 27. Machado- Pinilla R, Sanchez- Perez I, Murguia JR, Sastre L, Perona 
R. A dyskerin motif reactivates telomerase activity in X- linked 
dyskeratosis congenita and in telomerase- deficient human cells. 
Blood. 2008;111:2606- 2614.
 28. Manguan- Garcia C, Pintado- Berninches L, Carrillo J, et al. 
Expression of the genetic suppressor element 24.2 (GSE24.2) de-
creases DNA damage and oxidative stress in X- linked dyskeratosis 
congenita cells. PLoS One. 2014;9:e101424.
 29. Iarriccio L, Manguan- Garcia C, Pintado- Berninches L, et al. 
GSE4, a small dyskerin- and GSE24.2- related peptide, induces 
telomerase activity, cell proliferation and reduces DNA damage, 
oxidative stress and cell senescence in dyskerin mutant cells. PLoS 
One. 2015;10:e0142980.
 30. Pintado- Berninches L, Fernandez- Varas B, Benitez- Buelga C, 
et al. GSE4 peptide suppresses oxidative and telomere defi-
ciencies in ataxia telangiectasia patient cells. Cell Death Differ. 
2019;26(10):1998- 2014.
 31. Egusquiaguirre SP, Manguan- Garcia C, Pintado- Berninches L, 
et al. Development of surface modified biodegradable polymeric 
nanoparticles to deliver GSE24.2 peptide to cells: a promising ap-
proach for the treatment of defective telomerase disorders. Eur J 
Pharm Biopharm. 2015;91:91- 102.
 32. Egusquiaguirre SP, Manguan- Garcia C, Perona R, Pedraz JL, 
Hernandez RM, Igartua M. Development and validation of a rapid 
HPLC method for the quantification of GSE4 peptide in biode-
gradable PEI- PLGA nanoparticles. J Chromatogr B Analyt Technol 
Biomed Life Sci. 2014;972:95- 101.
 33. Almudever P, Milara J, De Diego A, et al. Role of tetrahydrobiop-
terin in pulmonary vascular remodelling associated with pulmo-
nary fibrosis. Thorax. 2013;68:938- 948.
 34. Cortijo J, Iranzo A, Milara X, et al. Roflumilast, a phosphodies-
terase 4 inhibitor, alleviates bleomycin- induced lung injury. Br J 
Pharmacol. 2009;156:534- 544.
 35. Milara J, Morcillo E, Monleon D, Tenor H, Cortijo J. Roflumilast 
prevents the metabolic effects of bleomycin- induced fibrosis in a 
murine model. PLoS One. 2015;10:e0133453.
 36. Giulietti A, Overbergh L, Valckx D, Decallonne B, Bouillon R, 
Mathieu C. An overview of real- time quantitative PCR: applica-
tions to quantify cytokine gene expression. Methods. 2001;25: 
386- 401.
 37. Sasser TA, Chapman SE, Li S, et al. Segmentation and measure-
ment of fat volumes in murine obesity models using X- ray com-
puted tomography. J Vis Exp. 2012;e3680.
 38. Mouratis MA, Aidinis V. Modeling pulmonary fibrosis with bleo-
mycin. Curr Opin Pulm Med. 2011;17:355- 361.
 39. Machado- Pinilla R, Carrillo J, Manguan- Garcia C, et al. Defects 
in mTR stability and telomerase activity produced by the Dkc1 
A353V mutation in dyskeratosis congenita are rescued by a pep-
tide from the dyskerin TruB domain. Clin Transl Oncol. 2012;14: 
755- 763.
 40. Freshney NW, Rawlinson L, Guesdon F, et al. Interleukin- 1 acti-
vates a novel protein kinase cascade that results in the phosphory-
lation of Hsp27. Cell. 1994;78:1039- 1049.
 41. Jang S, Ryu SM, Lee J, et al. Bleomycin inhibits proliferation via 
schlafen- mediated cell cycle arrest in mouse alveolar epithelial 
cells. Tuberc Respir Dis (Seoul). 2019;82:133- 142.
 42. Milara J, Hernandez G, Ballester B, et al. The JAK2 path-
way is activated in idiopathic pulmonary fibrosis. Respir Res. 
2018;19(1):24.
 43. Armanios M. Telomerase and idiopathic pulmonary fibrosis. Mutat 
Res. 2012;730:52- 58.
 44. Alder JK, Barkauskas CE, Limjunyawong N, et al. Telomere dys-
function causes alveolar stem cell failure. Proc Natl Acad Sci USA. 
2015;112:5099- 5104.
 45. Duffield JS, Lupher M, Thannickal VJ, Wynn TA. Host responses 
in tissue repair and fibrosis. Annu Rev Pathol. 2013;8:241- 276.
 46. Liu Y, Lu F, Kang L, Wang Z, Wang Y. Pirfenidone attenuates 
bleomycin- induced pulmonary fibrosis in mice by regulating Nrf2/
Bach1 equilibrium. BMC Pulm Med. 2017;17:63.
 47. Fernandez IE, Eickelberg O. The impact of TGF- beta on lung 
fibrosis: from targeting to biomarkers. Proc Am Thorac Soc. 
2012;9:111- 116.
 48. Inomata M, Kamio K, Azuma A, et al. Pirfenidone inhibits fibro-
cyte accumulation in the lungs in bleomycin- induced murine pul-
monary fibrosis. Respir Res. 2014;15(1):16.
 49. Li LF, Kao KC, Liu YY, et al. Nintedanib reduces ventilation- 
augmented bleomycin- induced epithelial- mesenchymal transition 
and lung fibrosis through suppression of the Src pathway. J Cell 
Mol Med. 2017;21:2937- 2949.
 50. Ding D, Zhu Q. Recent advances of PLGA micro/nanoparticles for 
the delivery of biomacromolecular therapeutics. Mater Sci Eng C 
Mater Biol Appl. 2018;92:1041- 1060.
 51. Chowdhury S, Guha R, Trivedi R, Kompella UB, Konar A, Hazra 
S. Pirfenidone nanoparticles improve corneal wound healing 
and prevent scarring following alkali burn. PLoS One. 2013;8: 
e70528.
 52. Trivedi R, Redente EF, Thakur A, Riches DW, Kompella UB. Local 
delivery of biodegradable pirfenidone nanoparticles ameliorates 
bleomycin- induced pulmonary fibrosis in mice. Nanotechnology. 
2012;23:505101.
 53. Townsley DM, Dumitriu B, Liu D, et al. Danazol treatment for 
telomere diseases. N Engl J Med. 2016;374:1922- 1931.
 54. Calado RT, Yewdell WT, Wilkerson KL, et al. Sex hormones, act-
ing on the TERT gene, increase telomerase activity in human pri-
mary hematopoietic cells. Blood. 2009;114:2236- 2243.
18 of 18 |   PINTADO- BERNINCHES ET Al.
 55. Cardenes N, Alvarez D, Sellares J, et al. Senescence of bone 
marrow- derived mesenchymal stem cells from patients with idio-
pathic pulmonary fibrosis. Stem Cell Res Ther. 2018;9:257.
 56. Planas- Cerezales L, Arias- Salgado EG, Buendia- Roldan I, et al. 
Predictive factors and prognostic effect of telomere shortening in 
pulmonary fibrosis. Respirology. 2019;24:146- 153.
SUPPORTING INFORMATION
Additional supporting information may be found online in 
the Supporting Information section.
How to cite this article: Pintado- Berninches L, 
Montes- Worboys A, Manguan- García C, et al. 
GSE4- loaded nanoparticles a potential therapy for 
lung fibrosis that enhances pneumocyte growth, 
reduces apoptosis and DNA damage. The FASEB 
Journal. 2021;35:e21422. https://doi.org/10.1096/
fj.20200 1160RR
